ArticleNature communications2025
Continuous targeted hypermutation with a tunable mutation window.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Evolutionary Landscape with Targeted In Vivo Hypermutations.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Targeted in vivo hypermutation drives rapid sequence diversification within specific DNA regions of living cells, enabling continuous evolution of biomolecules for enhanced functionality. In living organisms, this is prominently illustrated by the preferential somatic hypermutation of complementarity-determining regions during antibody affinity maturation. This particular targeting strategy employs focused mutagenesis in predefined, functionally important intragenic regions and should ideally allow for target range adjustment to support broader applications. However, molecular tools incorporating these features remain limited. Here, we present RESPECTevo, a system for focused hypermutation of endogenous and heterologous regions up to ~200 bp with predefined boundaries. By leveraging specific targeting capability, spacer length flexibility, and mismatch tolerance of the Escherichia coli Cascade complex, RESPECTevo enables highly specific targeted hypermutation, target range modulation, and continuous hypermutation across dual regions. Collectively, RESPECTevo serves as an efficient platform for hypermutating user-defined target regions in living cells, facilitating continuous protein evolution for biotechnological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.